STOCK TITAN
  1. Home
  2. News
  3. ELTX

Elicio Therapeutics Inc. - ELTX STOCK NEWS

Welcome to our dedicated news page for Elicio Therapeutics (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Elicio Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Elicio Therapeutics's position in the market.

News
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
Rhea-AI Summary
Elicio Therapeutics, a clinical-stage biotechnology company, will present new preliminary data from the ongoing AMPLIFY-7P Phase 1/2 study of ELI-002 7P at the 2024 ASCO Annual Meeting. The study focuses on patients with mKRAS-driven solid tumors and aims to stimulate an immune response against the seven KRAS mutations that drive 25% of all solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences clinical trial
-
News
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
Rhea-AI Summary
Elicio Therapeutics, Inc. announces pipeline updates for investigational cancer vaccines at AACR Annual Meeting. ELI-002 shows promising results in mKRAS-driven cancers, inducing durable and potent T cell responses. Preclinical data on ELI-007 and ELI-008 also demonstrate strong immune responses targeting BRAF and p53 mutations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
conferences clinical trial
-
News
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
Rhea-AI Summary
Elicio Therapeutics, Inc. reported financial results for 2023, highlighting progress in clinical trials and business development. Key points include poster presentations, ongoing Phase 2 trials, successful private placement, and financial data. The company's R&D expenses increased due to clinical trial initiation, while G&A expenses rose from operating as a public entity. Net loss decreased per share, primarily due to a reverse merger. Cash and cash equivalents grew by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
Rhea-AI Summary
Elicio Therapeutics, a biotechnology company, has entered into a subscription agreement to sell pre-funded warrants to purchase shares of its common stock in a private placement to GKCC, The gross proceeds are expected to be $6.0 million, with the net proceeds intended for the company's development pipeline and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28%
Tags
none
-
News
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced three upcoming poster presentations at the AACR Annual Meeting showcasing their innovative cancer vaccine candidates. The presentations will focus on the immunogenicity and efficacy of their AMP technology in targeting solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
conferences
-
News
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Elicio Therapeutics, Inc. (ELTX) is set to present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The CEO, Robert Connelly, will be presenting the clinical-stage biotechnology company's pipeline of novel immunotherapies for cancer treatment. The presentation will be available via live webcast and on-demand for 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences
News
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
Rhea-AI Summary
Elicio Therapeutics, Inc. announced promising preclinical data in Cancer Immunology Research, showing that their AMP immunotherapy platform enhanced TCR-T cell therapy, leading to complete eradication of solid tumors refractory to TCR-T cell monotherapy. The AMP treatment also promoted immune activation in lymph nodes, invigorating anti-tumor T cell immunity. The study demonstrated long-term protection against tumor recurrence and antigen spreading to additional tumor-associated antigens. Preclinical efficacy in solid tumors, including those with KRAS mutations, provides a strong rationale for the clinical advancement of a combination AMP immunotherapy strategy with TCR-T cell therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
clinical trial
-
News
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced the Phase 1/2 (AMPLIFY-7P) study design for ELI-002 7P, a therapeutic cancer vaccine for KRAS-mutated pancreatic ductal adenocarcinoma. The study aims to evaluate its antitumor activity and clinical benefit. ELI-002 7P is designed to stimulate an immune response against seven KRAS mutations, with preliminary data showing tumor biomarker reduction and reduced risk of relapse and death. The study includes Phase 1A safety evaluation, Phase 1B dose expansion, and a Phase 2 randomized study assessing disease-free survival. Key endpoints include biomarker reduction, median overall survival, safety, and iRECIST response rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
conferences clinical trial
-
News
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
Rhea-AI Summary
Elicio Therapeutics, Inc. (Nasdaq: ELTX) announced that its CEO and EVP will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference. The chat will be accessible via RSVP to a B. Riley Securities sales representative and a replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
conferences
News
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
Rhea-AI Summary
Elicio Therapeutics, Inc. (ELTX) announces the dosing of the first patient in the Phase 2 study of ELI-002 7P, a therapeutic cancer vaccine targeting seven common mutations in KRAS, at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research. The vaccine aims to treat pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. Elicio's proprietary AMP technology targets more mutations compared to other KRAS-targeted therapies, potentially benefiting a larger patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.53%
Tags
clinical trial
Stock ELTX logo
Elicio Therapeutics Inc.

Nasdaq:ELTX

ELTX Rankings

#4320 Ranked by Market Cap
#4148 Ranked by Stock Gains
N/A Ranked by Dividends

ELTX Stock Data

100.68M
5.39M
45.06%
5.31%
0.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About ELTX

elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer. by combining expertise in materials science and immunology, elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. the elicio amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body’s own system of defenses, to defeat cancer and stop its recurrence. this substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. elicio's lead amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. elicio was founded to expand and apply the ground-breaking amphiphile technology invented and developed in the labs of darrell